Nano-X Imaging Ltd. (NNOX) SEC Filings & Earnings Calls
EquiReason read 22 Nano-X Imaging Ltd. SEC filings in the last 12 months. Latest: 6-K on 2026-10-16 — Nanox provides preliminary Q3 2026 revenue of $4.3-4.4M (up from $3.4M YoY) but cash burn reduces cash to $26M from $60M; going concern doubt raised..
Source: SEC EDGAR filings · figures as of 2026-09-30 · read by EquiReason
- Market cap
- 26.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 19 Nov, in 26 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
16 Oct 20266-KNanox provides preliminary Q3 2026 revenue of $4.3-4.4M (up from $3.4M YoY) but cash burn reduces cash to $26M from $60M; going concern doubt raised.earningsopen
Figures in the filing · each found in the filing text
| Teleradiology revenue · teleradiology · Q3-2026 | $3M | 0% y/y |
| Imaging systems and OEM revenue · imaging systems and OEM · Q3-2026 | $300000.00 | +50% y/y |
| AI and software solutions revenue · AI and software · Q3-2026 | $1M | +900% y/y |
| Cash, cash equivalents, short-term and long-term restricted deposits · Q3-2026 | $26M | -57% y/y |
Risks flagged
Going concern risk due to insufficient cash to fund operations for at least one year
“Management expects that the Company’s cash and cash equivalents, and deposits, as of September 30, 2026, are not sufficient to support the Company’s operations under its current operating plans for at least one year from the date of this press release. These factors raise substantial doubt as to the Company’s ability to continue as a going concern.” · word for word
2 Oct 20266-KNasdaq notified Nano-X that bid price below $1.00 for 30 consecutive days; non-compliance with minimum bid price requirement; 180-day cure period until March 29, 2027.open
Risks flagged
Potential delisting from Nasdaq Global Market if bid price not regained by March 29, 2027.
“Nasdaq notice of non-compliance with Bid Price Requirement.”
17 Sep 20266-KAnnual shareholder meeting adjourned due to lack of quorum; Proposal 3 (CEO equity grants) withdrawn; urgent call to support Proposal 2 to increase authorized share capital to maintain Nasdaq listing and address going concern risk.open
Risks flagged
Going concern risk: cash resources insufficient to sustain operations without additional financing.
“Cash resources as of June 30, 2026 raised substantial doubt as to its ability to continue as a going concern.”
Nasdaq listing compliance risk: need for increased authorized share capital to support financing and maintain listing.
“Without the additional authorized share capital and the accompanying ability to finance the Company’s operations, the Company would be constrained in pursuing its operational goals.” · word for word
9 Sep 20266-KNano-X Imaging Ltd. announced Q2 2026 financial results via press release on September 9, 2026. The filing is a routine quarterly earnings report with no specific guidance or material non-financial events.earningsopen
Risks flagged
Limited visibility due to excerpt; no specific risks identified.
18 Aug 20266-KProxy statement for annual shareholder meeting; no material financial or operational event.open
Risks flagged
Going concern risk due to insufficient cash
“management expects that our cash and cash equivalents, and deposits as of March 31, 2026, were not sufficient to support our operations under our current operating plans for at least one year” · word for word
7 Aug 20266-KCompleted registered direct offering of 8M ordinary shares/pre-funded warrants and 8M ordinary warrants at $1.00 per unit, raising ~$8M gross proceeds; dilutive to existing shareholders.open
Risks flagged
Dilution risk from issuance of 8M shares and 8M warrants.
“8,000,000 ordinary shares and 8,000,000 ordinary warrants issued.”
6 Aug 20266-KNano-X Imaging announces $8M registered direct offering of 8M shares and warrants at $1.00/share, with warrants exercisable at $1.15. Also discloses ongoing impairment assessment that may materially impact Q2 2026 results.open
Risks flagged
Dilutive equity offering at $1.00/share with warrants at $1.15, indicating severe cash constraints and low market confidence
“8,000,000 ordinary shares (or pre-funded warrants) and warrants to purchase up to 8,000,000 ordinary shares at a combined purchase price of $1.00 per ordinary share and accompanying Warrant”
Ongoing comprehensive impairment assessment across all assets may result in material write-downs in Q2 2026
“the Company has initiated a comprehensive impairment assessment across all of its assets, including but not limited to long-lived assets and goodwill. ... the Company’s final reported financial results for the period may differ, potentially materially, from the preliminary estimates.” · word for word
23 Jul 20266-KNanox provides preliminary Q2 2026 revenue of $4.0-$4.1M, cash of $31.4M, and discloses substantial doubt about going concern due to insufficient cash for 12 months.open
Figures in the filing · each found in the filing text
| Teleradiology revenue · Teleradiology · Q2-2026 | $3M | +7% y/y |
| AI and software revenue · AI and Software · Q2-2026 | $1M | +900% y/y |
| Cash and deposits · Q2-2026 | $31M |
Risks flagged
Going concern risk: Cash insufficient for 12 months; company needs additional funding.
“Management expects that the Company’s cash and cash equivalents, and deposits, as of June 30, 2026, are not sufficient to support the Company’s operations under its current operating plans for at least one year from the date of this press release.” · word for word
Funding risk: No assurance of obtaining additional financing.
“There is no assurance that the Company will be able to obtain such funding.” · word for word
23 Jul 20266-KNanox files legal opinion for ATM offering; remaining $53.9M available under Sales Agreement, but notes insufficient authorized shares at current price.open
Figures in the filing · each found in the filing text
| Remaining ATM offering amount · Q3-2026 | $54M |
Risks flagged
Dilution risk: Continued ATM sales may dilute existing shareholders.
“Company has $53.9M remaining under ATM offering.”
Authorized share insufficiency: Current authorized shares may not cover full ATM amount.
“Based on the current market price of the Company’s ordinary shares, the number of ordinary shares authorized and available for issuance under the Articles of Association would be insufficient to permit the issuance and sale of all of the Prospective ATM Shares.” · word for word
25 Jun 20266-KNanox reported Q1 2026 revenue of $4.3M, up from $2.8M in Q1 2025, and improved gross margins, indicating operational progress.open
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $4M | +54% y/y |
| Teleradiology services revenue · Teleradiology services · Q1-2026 | $3M | +19% y/y |
| Imaging systems and OEM services revenue · Imaging systems and OEM services · Q1-2026 | $167000.00 | +406% y/y |
| AI and software solutions revenue · AI and software solutions · Q1-2026 | $1M | +400% y/y |
| GAAP gross loss · Q1-2026 | $3M | -13% y/y |
| Non-GAAP gross loss · Q1-2026 | $200000.00 | -50% y/y |
| Research and development expenses · Q1-2026 | $5M | -4% y/y |
| Sales and marketing expenses · Q1-2026 | $2M | +144% y/y |
| General and administrative expenses · Q1-2026 | $5M | +2% y/y |
Risks flagged
Commercialization pace depends on market adoption, site readiness, and regulatory approvals
“the pace of commercialization will continue to depend on a range of factors, including market adoption, customer demand, site readiness, construction timelines, regulatory approvals, and the performance of our partners.” · word for word
30 Apr 202620-FCompany announced restructuring plan including impairment of $17.5M and shift to outsourced manufacturing, with net loss widening to $75M.open
Figures in the filing · each found in the filing text
| Total Revenue · FY2025 | $13M | +15% y/y |
| Teleradiology Services Revenue · Teleradiology services · FY2025 | $12M | +13% y/y |
| Scan Services and Nanox.ARC/CONNECT Revenue · Nanox.ARC · FY2025 | $478000.00 | +70% y/y |
| AI Solutions Revenue · AI and software solutions · FY2025 | $958000.00 | +32% y/y |
| Cost of Revenue · FY2025 | $26M | +18% y/y |
| Net Loss · FY2025 | $-75M | +40% y/y |
| Research and Development Expenses · FY2025 | $19M | -5% y/y |
| General and Administrative Expenses · FY2025 | $22M | -4% y/y |
| Impairment of Long-Lived Assets · Nanox ARC · FY2025 | $18M |
Risks flagged
Restructuring execution risk
“This includes transitioning away from certain manufacturing activities at our facility in South Korea, starting in the fourth quarter of 2025, and moving from a company-owned manufacturing model to a more fully outsourced approach.” · word for word
Litigation and regulatory risk
“The Division of Enforcement of the U.S. Securities & Exchange Commission (the “SEC” or the “Commission”) conducted an investigation to determine whether there had been any violations of the federal securities laws... The Company paid a civil penalty in the amount of $650,000 and was permanently enjoined...” · word for word
Going concern risk
“Net loss was $75 million for the year ended December 31, 2025, and $53.5 million for the year ended December 31, 2024.” · word for word
Shareholder dilution risk
“In return for the release, and without admission of any liability, we issued the shareholder 450,000 ordinary shares.” · word for word
20 Apr 20266-KNanox (NNOX) filed a 6-K with Q4 2025 results: revenue $3.7M (up from $3.0M YoY), net loss $33.4M (vs $14.1M) due to $17.5M impairment. Also announced CFO transition, distribution agreement for 300 systems, and restructuring.open
Figures in the filing · each found in the filing text
| revenue · Q4-2025 | $4M | +23% y/y |
| net loss · Q4-2025 | $-33M | |
| impairment of long-lived assets · Q4-2025 | $18M |
Risks flagged
Geopolitical risk in Middle East could impact operations.
“Company is closely monitoring the evolving geopolitical situation in the Middle East.” · word for word
Restructuring and impairment indicate operational challenges.
“Restructuring of Korean facility and $17.5M impairment.”
3 Feb 20266-KNano-X Imaging received FDA 510(k) clearance for TAP2D image enhancement capability for Nanox.ARC systems, enabling 2D views from tomosynthesis scans without extra radiation.open
Risks flagged
Regulatory clearance is a milestone but does not guarantee commercial success; reliance on future clearances for adjunctive use removal.
“Forward-looking statements highlight risks related to development, commercialization, and regulatory approvals.”
26 Nov 20256-KRegistered direct offering of 3,826,530 ordinary shares at $3.92 per share for gross proceeds of approximately $15.0 million.open
Figures in the filing · each found in the filing text
| Shares offered | 3,826,530 | |
| Offering price per share | $3.92 | |
| Gross proceeds | $15M |
Risks flagged
Dilution from share issuance.
“Issuance of 3,826,530 ordinary shares.”
24 Nov 20256-KRegistered direct offering of 3,826,530 ordinary shares at $3.92 per share; press release furnished.open
Figures in the filing · each found in the filing text
| Shares offered | 3,826,530 | |
| Offering price per share | $3.92 | |
| Gross proceeds | $15M |
Risks flagged
Dilution from share issuance.
“Issuance of 3,826,530 ordinary shares.”
20 Nov 20256-KRevenue increased to $3.4M from $3.0M YoY; teleradiology gross profit margin improved to 25% from 13%; net loss stable at $13.7M; management tone positive on commercialization progress.open
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $3M | +13% y/y |
| Net loss · Q3-2025 | $-14M | +1% y/y |
| Teleradiology revenue · teleradiology · Q3-2025 | $3M | +19% y/y |
| Teleradiology gross profit margin (GAAP) · teleradiology · Q3-2025 | 25.0% | |
| Imaging systems revenue · imaging systems · Q3-2025 | $175000.00 | +503% y/y |
| AI solutions revenue · AI solutions · Q3-2025 | $142000.00 | -67% y/y |
| Research and development expenses · Q3-2025 | $5M | -2% y/y |
| Sales and marketing expenses · Q3-2025 | $2M | +67% y/y |
| General and administrative expenses · Q3-2025 | $5M | -7% y/y |
Guidance
On track to meet year-end system deployment target
Management reaffirms year-end deployment target; revenue growth and margin improvement in teleradiology; acquisition to support AI growth.
Risks flagged
Continued gross loss on imaging systems and AI solutions segments indicates scalability challenges.
“Imaging systems gross loss $1.7M; AI solutions GAAP gross loss $1.9M.”
Net loss remains high relative to revenue, indicating ongoing cash burn.
“Net loss $13.7M on revenue $3.4M.”
19 Nov 20256-KNanox announces agreement to acquire VasoHealthcare IT for up to $800K to accelerate U.S. AI solutions deployment; small tuck-in acquisition with strategic rationale.acquisitionopen
Figures in the filing · each found in the filing text
| Acquisition consideration | $800000.00 | |
| Cash payment at closing | $200000.00 | |
| Performance-based earnout | $600000.00 |
Risks flagged
Acquisition integration risk; earnout contingent on revenue retention.
“Earnout payments contingent upon revenue retention targets.”
Nano-X Imaging Ltd. — questions
- What did Nano-X Imaging Ltd. file recently?
- 22 SEC filings in the last 12 months. Latest: 6-K on 2026-10-16 — Nanox provides preliminary Q3 2026 revenue of $4.3-4.4M (up from $3.4M YoY) but cash burn reduces cash to $26M from $60M; going concern doubt raised.
Every figure on this page comes from Nano-X Imaging Ltd.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.